Press release
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
EXPAND clinical trial to be presented; data support Fetal Focus™ sgNIPT for inherited conditions AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ:
About this update from Natera, Inc.
[{"type":"text","content":"\nEXPAND clinical trial to be presented; data support Fetal Focus™ sgNIPT for inherited conditions\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026.\n\n\nEXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera’s proprietary, ultra-sensitive LinkedSNP™ technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions.\n\n\nAs previously announced, EXPAND validated Fetal Focus’ ability to identify a broad range of clinically relevant inherited conditions with high accuracy. The oral presentation will detail the study’s key results, along with its robust design, including confirmation of all outcomes against genetic truth.\n\n\n“Being selected for a plenary session at SMFM highlights the high quality of the EXPAND data and its role in advancing prenatal screening,” said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women’s health at Natera. “Supporting women’s health is central to Natera’s mission. EXPAND reflects our ongoing commitment to generating high-quality clinical evidence that delivers actionable insights in prenatal care.”\n\n\nIn addition to EXPAND, Natera and its collaborators will deliver a second oral presentation at SMFM highlighting data from VANISH, a prospective clinical trial which validates the unique ability of Panorama™ NIPT to interpret cell-free DNA patterns in vanishing twin pregnancies.\n\n\nThe full list of Natera presentations at SMFM includes:\n\n\nFebruary 11, 8:45 AM PT | Presentation # 4 (Oral Plenary Presentation)\nPresenter: Rajeevi Madankumar, M.D.\nPerformance of a single gene non-invasive prenatal screening test for recessive conditions\n\n\nFebruary 11, 10:30 AM PT | Presentation # 145 (Poster)\nPresenter: Vivienne Souter, M.D.\nCarrier Screening as a Pathway to In-Utero Therapy\n\n\nFebruary 12, 1:00 PM PT | Presentation # 65 (Oral Presentation)\nPresenter: Lorraine Dugoff, M.D.\nDevelopment and Validation of a SNP-based cfDNA test for vanishing twin pregnancies: The VANISH Tria...